429 related articles for article (PubMed ID: 16841626)
1. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.
Kornstein SG; Wohlreich MM; Mallinckrodt CH; Watkin JG; Stewart DE
J Clin Psychiatry; 2006 May; 67(5):761-70. PubMed ID: 16841626
[TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J
BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
[TBL] [Abstract][Full Text] [Related]
4. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates?
Fava M; Mallinckrodt CH; Detke MJ; Watkin JG; Wohlreich MM
J Clin Psychiatry; 2004 Apr; 65(4):521-30. PubMed ID: 15119915
[TBL] [Abstract][Full Text] [Related]
5. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.
Lewis-Fernández R; Blanco C; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Clin Psychiatry; 2006 Sep; 67(9):1379-90. PubMed ID: 17017824
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine for the treatment of major depressive disorder in women ages 40 to 55 years.
Burt VK; Wohlreich MM; Mallinckrodt CH; Detke MJ; Watkin JG; Stewart DE
Psychosomatics; 2005; 46(4):345-54. PubMed ID: 16000678
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine in the treatment of major depressive disorder: an open-label study.
Hudson JI; Perahia DG; Gilaberte I; Wang F; Watkin JG; Detke MJ
BMC Psychiatry; 2007 Aug; 7():43. PubMed ID: 17725843
[TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.
Bailey RK; Mallinckrodt CH; Wohlreich MM; Watkin JG; Plewes JM
J Natl Med Assoc; 2006 Mar; 98(3):437-47. PubMed ID: 16573311
[TBL] [Abstract][Full Text] [Related]
11. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.
Gueorguieva R; Mallinckrodt C; Krystal JH
Arch Gen Psychiatry; 2011 Dec; 68(12):1227-37. PubMed ID: 22147842
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.
Brecht S; Courtecuisse C; Debieuvre C; Croenlein J; Desaiah D; Raskin J; Petit C; Demyttenaere K
J Clin Psychiatry; 2007 Nov; 68(11):1707-16. PubMed ID: 18052564
[TBL] [Abstract][Full Text] [Related]
13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
Goldstein DJ; Mallinckrodt C; Lu Y; Demitrack MA
J Clin Psychiatry; 2002 Mar; 63(3):225-31. PubMed ID: 11926722
[TBL] [Abstract][Full Text] [Related]
15. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.
Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ
Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
17. Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression.
Shelton RC; Andorn AC; Mallinckrodt CH; Wohlreich MM; Raskin J; Watkin JG; Detke MJ
Int Clin Psychopharmacol; 2007 Nov; 22(6):348-55. PubMed ID: 17917553
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial.
Detke MJ; Lu Y; Goldstein DJ; Hayes JR; Demitrack MA
J Clin Psychiatry; 2002 Apr; 63(4):308-15. PubMed ID: 12000204
[TBL] [Abstract][Full Text] [Related]
19. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Nierenberg AA; Greist JH; Mallinckrodt CH; Prakash A; Sambunaris A; Tollefson GD; Wohlreich MM
Curr Med Res Opin; 2007 Feb; 23(2):401-16. PubMed ID: 17288694
[TBL] [Abstract][Full Text] [Related]
20. Relationship between TSH levels in the normal range and short-term duloxetine efficacy.
Corruble E; Goldberger C; Spann M
J Affect Disord; 2010 Jun; 123(1-3):312-6. PubMed ID: 19825504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
